Interactive Features

Quiz

Quiz: Is This Monotherapy Safe, Well-Tolerated in Newly Diagnosed AML?

01/20/2022

According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?

According to data from a phase...

01/20/2022

Oncology

Test Your Knowledge

Quiz: Does This Monotherapy Induce High CR/CRi Rates in AML?

01/10/2022

True or false: Gilteritinib monotherapy induces a high CR/CRi rate in older newly-diagnosed patients with FLT3-mutated AML.

True or false: Gilteritinib...

01/10/2022

Oncology

Test Your Knowledge

Quiz: Does This Monotherapy Induce High CR/CRi Rates in AML?

01/10/2022

True or false: Gilteritinib monotherapy induces a high CR/CRi rate in older newly-diagnosed patients with FLT3-mutated AML.

True or false: Gilteritinib...

01/10/2022

Oncology

Test Your Knowledge

Quiz: Novel IMGN632-Based Triplet for Patients With R/R AML

12/01/2021

Does IMGN632 plus azacitidine and venetoclax yield anti-leukemia activity in patients with R/R AML?

Does IMGN632 plus azacitidine...

12/01/2021

Oncology

Test Your Knowledge

Quiz: Novel IMGN632-Based Triplet for Patients With R/R AML

12/01/2021

Does IMGN632 plus azacitidine and venetoclax yield anti-leukemia activity in patients with R/R AML?

Does IMGN632 plus azacitidine...

12/01/2021

Oncology

Test Your Knowledge

Quiz: Is Decitabine an Alternative Chemo Regimen for AML?

11/22/2021

True or false: A study on the efficacy of decitabine found it cannot be used as an alternative first-line chemotherapy regimen for patients with AML.

True or false: A study on the...

11/22/2021

Oncology

Test Your Knowledge

Quiz: Is Decitabine an Alternative Chemo Regimen for AML?

11/22/2021

True or false: A study on the efficacy of decitabine found it cannot be used as an alternative first-line chemotherapy regimen for patients with AML.

True or false: A study on the...

11/22/2021

Oncology

Test Your Knowledge

Quiz: Venetoclax Plus CIT Improves OS for Which Type of Cancer?

11/01/2021

Venetoclax when added to intensive chemotherapy has been shown to improve OS for patients with which of the following cancers?

Venetoclax when added to...

11/01/2021

Oncology

Test Your Knowledge

Quiz: Venetoclax Plus CIT Improves OS for Which Type of Cancer?

11/01/2021

Venetoclax when added to intensive chemotherapy has been shown to improve OS for patients with which of the following cancers?

Venetoclax when added to...

11/01/2021

Oncology

Test Your Knowledge

Quiz: Is There an Alternative CIT Regimen for AML?

10/28/2021

Which regimen can be used as an alternative first-line chemotherapy for elderly patients with AML?

Which regimen can be used as an...

10/28/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology